RankAlpha logo
Back to Rankings

FATE

Fate TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
View Chart
Current thesis
Fate has a defined near-term clinical milestone in RECLAIM-LN, FDA CDRP and RMAT support for FT819, and management reported an operating runway into 2028 after reducing first-quarter operating expenses by 20% year over year [#SEC-8K-2026-05-13].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Additional equity compensation or financing could dilute shareholders [#8-K-2026-06-15].
Momentum
95
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.30 · Bull $5.40 · Bear $1.75
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-15 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.41
Why
Momentum95 · Δ7d +0.9
Value41 · Δ7d -0.1
Sentiment100 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
95
26% active weight
Current posture
7d trendSoftening
Δ7d
+0.9
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
100
34% active weight
Current posture
7d trendImproving
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 94.6 / Value 41.1 / Sentiment 100.0

Fundamentals (TTM)
As of 2026-07-15
Market Cap
$348.51M
Beta
2.25
Shares Out
116.56M
P/E (TTM) · Derived
-2.6
P/S (TTM)
16.32
P/FCF (TTM) · Derived
-3.30
Rev YoY
-20.3%
EPS YoY
-18.2%
Gross Margin
-97.7%
Op Margin
-2448.2%
Net Debt
-$125.81M
Current Ratio
5.85
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology